Stay updated on Pembrolizumab in Advanced NSCLC: 2nd Line Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Advanced NSCLC: 2nd Line Clinical Trial page.

Latest updates to the Pembrolizumab in Advanced NSCLC: 2nd Line Clinical Trial page
- Check4 days agoChange DetectedLung cancer is added to related topics with a MedlinePlus Genetics link for educational resources.SummaryDifference0.2% 
- Check11 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check26 days agoChange DetectedUpdated version to v3.2.0 and removed MedlinePlus Genetics topic: Lung cancer; added a government funding/operating status notice referencing NIH and OPM.SummaryDifference3% 
- Check33 days agoChange DetectedCore content updated with a new MedlinePlus Genetics topic on Lung cancer and a version upgrade to v3.1.0; older revision reference v3.0.2 was removed.SummaryDifference0.2% 
- Check40 days agoChange DetectedRemoved a MedlinePlus Genetics topic entry for Lung cancer from the page, reducing coverage of that topic without adding new content.SummaryDifference0.2% 
- Check47 days agoChange DetectedPage updated to revision v3.0.2, replacing v3.0.1. The Back to Top link was removed, with no other substantive changes observed.SummaryDifference0.1% 
- Check54 days agoChange DetectedThe web page has been updated to include information on Lung cancer under MedlinePlus Genetics topics, and the version has been revised from v3.0.0 to v3.0.1.SummaryDifference0.3% 
Stay in the know with updates to Pembrolizumab in Advanced NSCLC: 2nd Line Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Advanced NSCLC: 2nd Line Clinical Trial page.